Articles On Starpharma Holdings (ASX:SPL)

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. At the time of writing, the benchmark index is down 1.8% to 7,233.7 points. Four ASX shares that have fallen more than mo...

Summary The ASX dropped over 2% to hit intraday low of 7,216.60, led by sharp sell-off in financials, energy, and industrial stocks. The market sentiments were dented by the US Fed official comment that the central bank might raise int...

Starpharma Holdings Limited (ASX: SPL) shares have taken a hit this morning. At the time of writing, the Starpharama share price is trading 9.71% lower at $1.535. What’s dragging the Starpharma share price down? Starpharma shares are wel...

Pharmaceutical company Starpharma (ASX: SPL) and its retail partner LloydsPharmacy have paused sales of SPL's anti-COVID nasal spray VIRALEZE in the UK after regulators raised concerns over promotional claims. Shares in SPL have dived in...

Summary The S&P/ASX 200 closed higher by 9.90 points or 0.13%, at 7368.90. The index ended higher for the fifth straight week, gaining 0.77% in the last five days. BNPL firm Zip Co emerged as the top gainer, while energy firm Sant...

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ — New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. Major b...

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ — New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. Major b...

The S&P/ASX 200 Index (ASX: XJO) is back on form on Friday and on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.3% to 7,382 points Four ASX shares that are climbing more than most today...

The Starpharma Holdings Limited (ASX: SPL) share price is on course to end the week on a strong note. At the time of writing, the dendrimer products developer’s shares are up 7% to $1.66. Why is the Starpharma share price pushing higher? T...

Starpharma (ASX:SPL) has announced that its Australian developed anti-COVID nasal spray Viraleze is now registered for use in India.

The Starpharma Holdings Limited (ASX: SPL) share price has bounced back from weakness this morning and is pushing higher late on Friday. In afternoon trade, the biotechnology company’s shares are up 1% to $1.69. This latest gain means the...

01 June 2021 - Biopharmaceutical company Starpharma (ASX:SPL) claims the company’s nasal spray product is a highly efficacious means of protection from the UK variant of the corona…

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Tuesday morning. At the time of writing, the dendrimer products developer’s shares are up over 2% to $1.84. This latest gain means the Starpharma share price is no...

Testing by the Scripps Research Institute has found Starpharma's (ASX:SPL) Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19.

Shares in mid-cap ASX biopharmaceuticals company Starpharma Holdings Limited (ASX: SPL) have endured a volatile start to 2021. After surging to an all-time high of $2.52 by mid-February, the company’s shares have now plunged more than 35%...

Federal Treasurer Josh Frydenberg unleashed a wave of new spending last night that will likely give several ASX shares a nice boost. If you haven’t already heard, spending is the new fiscal conservatism! While many of the details from the...

Summary The S&P/ASX200 was trading lower by 79 points or 1.10% at 7093 at the close. Ten of 11 sectors traded in red, while Information Technology fell over 4%. The top five losers on the ASX were PointsBet, Afterpay (ASX:APT), Re...

The Starpharma Holdings Limited (ASX: SPL) share price is heading downwards today. At the time of writing, shares in the pharmaceutical company are swapping hands for $1.71 – down 2.56%. By comparison, the S&P/ASX 200 Index (ASX: XJO)...

As the ASX wobbles into afternoon trading, Starpharma Holdings Ltd (ASX:SPL) share price is up 2.24% at time of writing.Putting the biotech stock in the green on a day that has left many stocks in the red... The post SPL Shares Up — COVID-1...

In late morning trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and tumbling lower. At the time of writing, the benchmark index is down 0.4% to 7,067.1 points. Four ASX shares that are not letting that hold them back are listed...

The Starpharma Holdings Limited (ASX: SPL) share price has been a strong performer on Thursday. At the time of writing, the dendrimer products developer’s shares are up 6% to $1.89. Why is the Starpharma share price racing higher? Investor...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back the majority of its morning gains and is trading just a fraction higher for the day. At the time of writing, the benchmark index is up slightly to 7,030.3 points. Four...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

Starpharma Holdings Limited (ASX: SPL) shares are having a mixed morning after the Aussie healthcare group’s latest quarterly update. The Starpharma share price opened today’s session 5.88% higher at $1.80. However, since then, the company...

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

While the Starpharma Holdings Limited (ASX: SPL) share price is having a reasonable day today – up 0.77%, it’s done very well so far in 2021. At the time of writing, shares in the pharmaceutical company are trading for $1.96 cents each. Wh...

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

The Starpharma Holdings Limited (ASX: SPL) share price has come under pressure on Tuesday despite the release of a positive announcement. In afternoon trade, the dendrimer products developer’s shares are down 4.5% to $1.99. What did Starph...

Source: Source: janews , Shutterstock   Healthcare takes over 1/10th per cent of the GDP of the most developed countries and the US contributes the most to this industry. As the coronavirus pandemic hit hard every industry, including hea...

It's been a rocky month of trading for Starpharma Holdings Ltd [ASX:SPL] investors. The ASX SPL share price hitting a low point of $1.77 two weeks ago, only to now rebound back to $2.14 last Monday... The post Starpharma Shares Down Despite...

25 Mar 2021 - Starpharma (ASX: SPL) signs an agreement with Lloyds Pharmacy in the UK for the distribution of its VIRALEZE antiviral nasal spray.

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Thursday morning. At the time of writing, the dendrimer products developer’s shares are up 3.5% to $2.10. Why is the Starpharma share price pushing higher? Investo...

Global stock markets dipped Stock markets dipped globally on fears over a potential third lockdown in Europe. Wall Street has seesawed throughout the week, as European shares hit a two-week low. Dow Jones was down 0.01%, S&P 500 fell by...

Pharmaceuticals manufacturer Starpharma (ASX: SPL) will commence the rollout of its COVID-killing nasal spray in the UK after signing a deal with a major pharmacy chain. The group's antiviral nasal spray called VIRALEZE will be stocked by...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Tuesday morning. At one stage today, the dendrimer products developer’s shares were up as much as 6% to $1.98. At the time of writing, Starpharma share price has e...

16 Mar 2021 - Starpharma (ASX:SPL) says its second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regressio…

During February the ASX200 recorded a fifth consecutive monthly rise with the materials and financial sectors leading the way. -The ASX200 rose 1% during February-Value and large caps outperformed-The Australian 10-year bond yield rose 79 b...

Source: Voronin76,Shutterstock Summary World-leading regenerative medicine company Orthocell revealed that CelGro® Dental was included on the Australian Prostheses List. Additional antiviral testing proved that Starpharma’s antiviral...

Strong performing ASX healthcare shares came few and far between in February. The S&P/ASX Health Care Index (ASX: XHJ) was down 3% for the month, compared to the 1% increase in the ASX 200.   From respiratory devices, vaccine producers...

The Starpharma Holdings Limited (ASX: SPL) share price is in the red today, slipping 0.47% at the time of writing to $2.13. The biotechnology company develops new pharmaceutical and medical products based on proprietary polymers called den...

Source: Shutterstock Summary Pharmaceutical and medical products manufacturer Starpharma achieved multiple product development milestones during the challenging first half of 2021. The Company has completed the development of VIRALEZE...

Just because we have vaccines, doesn’t meant we can’t fight off this virus in other ways. Which is precisely what Starpharma Holdings Ltd [ASX:SPL] has been doing. And today the stock is trading 6.36% higher thanks to their ongoing fight.....

Source:Sutterstock Summary ASX 300-listed global biopharmaceutical company Starpharma has successfully registered its antiviral nasal spray in Europe, including the UK. The European launch of the nasal spray is on track and anticipate...

The Starpharma Holdings Limited (ASX: SPL) share price has been a very strong performer on Tuesday. At one stage today, the dendrimer products developer’s shares were up as much as 13% to $2.49. When the Starpharma share price hit that lev...

23 Feb 2021 - Pharmaceutical developer Starpharma (ASX:SPL) has received EU approval for the company’s antiviral nasal spray Viraleze.

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to continue its losing streak. The benchmark index is currently down slightly at 6,773 points. Four ASX shares that have not let that hold them back are listed below....

Starpharma (ASX:SPL) says it has received confirmation that the VIRALEZE antiviral nasal spray has been successfully registered for sale in Europe and the UK.

Australian pharmaceutical company Starpharma's (ASX: SPL) anti-COVID nasal spray VIRALEZE has been approved for sale in Europe and the UK today, and is now on track to launch next month. Shares in SPL have spiked on the announcement, up m...

The S&P/ASX 200 Index (ASX: XJO) has started the week strongly and is racing higher. In afternoon trade, the benchmark index is up 0.9% to 6,868.2 points. Four ASX shares that have failed to follow the market higher today are listed be...

Summary ASX 300-listed global biopharmaceutical company Starpharma has signed a Research Agreement with MSD. Under this agreement, MSD will perform a preclinical research evaluation of dendrimer-based ADCs utilising proprietary DEP® te...